RCHOP

DRUG2 trials

Sponsors

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, French Innovative Leukemia Organisation

Conditions

LymphomaRichter Syndrome

Phase 2

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

CompletedNCT02012088

Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaLymphoma

Start: 2013-10-11End: 2021-08-31Updated: 2024-02-26

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

CompletedNCT03931642

French Innovative Leukemia OrganisationRichter Syndrome

Start: 2019-07-05End: 2022-10-21Updated: 2023-05-24

Related Papers

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.

2024-08-099 citations

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood2022-11-1516 citations

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Blood2021-11-059 citations

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Cancer Medicine2021-01-2528 citations

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Blood2020-11-042 citations

<scp>R‐COMP</scp> VS <scp>R‐CHOP</scp> AS FIRST‐LINE THERAPY FOR DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH <scp>GELTAMO</scp> GROUP

Hematological Oncology2017-06-01

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Blood2016-12-021 citations